Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.

ABSTRACT:

Importance

Patients with estrogen receptor (ER)-positive breast cancer have a long-term risk for fatal disease. However, the tumor biological factors that influence the long-term risk and the benefit associated with endocrine therapy are not well understood.

Objective

To compare the long-term survival from tamoxifen therapy for patients with luminal A or luminal B tumor subtype.

Design, setting, and participants

Secondary analysis of patients from the Stockholm Tamoxifen (STO-3) trial conducted from 1976 to 1990, which randomized postmenopausal patients with lymph node-negative breast cancer to receive adjuvant tamoxifen or no endocrine therapy. Tumor tissue sections were assessed in 2014 using immunohistochemistry and Agilent microarrays. Only patients with luminal A

SUBMITTER: Yu NY 

PROVIDER: S-EPMC6692699 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature